Saxagliptin (BMS -). FDA's Endocrinologic and Metabolic Drugs. Advisory Committee. Briefing Document for April 2009 Meeting.
A Phase 3 Study of BMS - in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and.
Saxagliptin is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD).